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OBJECTIVE — To investigate serum levels of the adipokine chemerin in patients on chronic hemo-
dialysis (CD) as compared with control patients with a glomerular ﬁltration rate (GFR) 50 ml/min.
RESEARCH DESIGN AND METHODS — Chemerin was quantiﬁed by ELISA in control
patients(n60)andCDpatients(n60)andcorrelatedwithclinicalandbiochemicalmeasuresof
renal function, glucose, and lipid metabolism, as well as inﬂammation, in both groups.
RESULTS — Median serum chemerin levels were more than twofold higher in CD patients
(542.2 g/l) compared with subjects with a GFR 50 ml/min (254.3 g/l) (P  0.001). Fur-
thermore, GFR, as assessed by the original Modiﬁcation of Diet in Renal Disease formula,
independently predicted circulating chemerin concentrations in multiple regression analyses in
both control patients (P  0.05) and CD patients (P  0.01).
CONCLUSIONS — We demonstrate that markers of renal function are independently re-
lated to circulating chemerin levels.
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R
ecently, chemerin has been identi-
ﬁed as a novel adipocyte-secreted
factor playing a crucial role in adi-
pocyte differentiation and insulin signal-
ing (1–4). Several studies have quantiﬁed
circulating chemerin in humans. Thus,
tworeportsfoundanindependentassoci-
ation between chemerin and markers of
inﬂammation (5,6). Furthermore, corre-
lations between circulating chemerin and
metabolic syndrome–related parameters
have been described (6–8). In contrast to
other adipokines (9–12), no data have
beenpublishedsofarabouttherelationof
chemerin to renal function.
RESEARCH DESIGN AND
METHODS
Subjects
The design of the study has recently been
described in detail (9–12). Brieﬂy, 120
Caucasian men (n  62) and women (n 
58)wererecruitedwith60patientshavinga
glomerular ﬁltration rate (GFR) 50 ml/
min (control patients), as assessed by the
original Modiﬁcation of Diet in Renal Dis-
ease formula (13), and 60 patients being on
hemodialysis. Thirty control patients and 32
chronic hemodialysis (CD) patients had type
2 diabetes. Patients with active inﬂammatory
diseases including pneumonia, urinary tract
infection, endocarditis, sinusitis, and cholan-
gitis were excluded from the study. Further-
more, patients with end-stage malignant
diseases of any origin were excluded. Inactive
systemic lupus erythematodes, stable coro-
nary heart disease, and previous stroke were
not exclusion criteria. The study was ap-
proved by the local ethics committee, and all
subjectsgavewritteninformedconsentbefore
taking part in the study.
Assays
Blood samples were taken after an over-
night fast. In CD patients, blood was
drawn just before hemodialysis started.
Chemerin (BioVendor, Modrice, Czech
Republic) (intraassay coefﬁcient of var-
iation[CV]5.1–7.0%,interassayCV6.9–
8.3%), adiponectin (Mediagnost,
Reutlingen, Germany) (intraassay CV
4.7%, interassay CV 6.7%), and lep-
tin (Mediagnost, Reutlingen, Germany)
(intraassay and interassay CV 10%)
were determined with ELISAs according
to the manufacturers instructions. Free
fatty acids, cholesterol, triglycerides, C-
reactive protein (CRP), insulin, and other
routine laboratory parameters were mea-
sured in a certiﬁed laboratory.
Statistical analysis
SPSS software version 15.0 (SPSS, Chi-
cago, IL) was used for all statistical anal-
yses as further speciﬁed in the RESULTS
section and in the legend for Table 1. Dis-
tribution was tested for normality using
Shapiro-Wilk W test, and non-normally
distributed parameters were logarithmi-
cally transformed before multivariate
analyses.
RESULTS
Chemerin serum levels are increased
in CD patients
Table 1 summarizes clinical characteris-
ticsofthesubgroupsstudied(controland
CD). In Table 1 and throughout the text,
all continuous variables are given as me-
dian  interquartile range. Median circu-
lating chemerin was more than twofold
higherinCDpatients(542.298.1g/l)
compared with control patients (254.3 
88.7 g/l, P  0.001) (Table 1). In con-
trast, a signiﬁcant difference in chemerin
concentrations could not be demon-
strateddependingonsex(femalesubjects
324.4  284.6 g/l and male subjects
443.6  315.2 g/l) and type 2 diabetes
(type 2 diabetes 388.1  303.7 g/l and
non-type 2 diabetes 331.0  274.6 g/l).
CD patients had a signiﬁcantly lower BMI
compared with that in control patients
(P  0.05) (Table 1).
Univariate correlations
Using the Spearman rank correlation
method, serum chemerin concentrations
positivelycorrelatedwithBMI(r0.398,
P  0.002), fasting insulin (FI) (r 
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0.001), and CRP (r  0.256, P  0.049)
in control patients. In addition, chemerin
negatively correlated with GFR (r 
0.372, P  0.003) in control patients.
In CD patients, circulating chemerin lev-
els were negatively associated with GFR
(r  0.413, P  0.001).
Multivariate regression analyses
Multiple linear regression analysis revealed
that GFR (logarithmically transformed
[log], standardized -coefﬁcient 
0.337, P  0.013) but not FI (log, stan-
dardized -coefﬁcient  0.186, P 
0.128), leptin (log, standardized -coef-
ﬁcient  0.091, P  0.588), and CRP
(log, standardized -coefﬁcient  0.138,
P  0.236) remained independently as-
sociated with circulating chemerin (log)
levels in control patients after adjustment
for age (standardized -coefﬁcient 
0.033, P  0.793) and sex (standard-
ized-coefﬁcient0.250,P0.097).A
similar result was obtained when BMI in-
stead of leptin was included in the model
(data not shown). In addition, GFR (log,
standardized -coefﬁcient  0.351,
P  0.007) predicted circulating
chemerin (log) independent of age (stan-
dardized -coefﬁcient  0.223, P 
0.072) and sex (standardized -coefﬁ-
cient  0.076, P  0.546) in CD
patients.
CONCLUSIONS— In the current
study, we show for the ﬁrst time that cir-
culating chemerin levels are more than
twofold higher in CD patients compared
with control patients. Furthermore, CD
is a strong independent predictor of
chemerin concentrations in multivariate
analysis(datanotshown).Moreover,GFR
remains independently associated with
circulating chemerin in multivariate anal-
ysis in both control patients and CD pa-
tients. In these cases, functional studies
including urine analyses should be per-
formed to deﬁne whether renal elimina-
tion inﬂuences serum levels of chemerin.
Furthermore, renal production of
chemerin has been shown (1–4), and it
should be determined to what extent this
kidney-derived chemerin contributes to
circulating levels of the adipokine in con-
trol patients and CD patients. Moreover,
because chemerin modulates inﬂamma-
tion (14,15), its contribution to renal dis-
ease–associated metabolic and vascular
complications should be elucidated in fu-
ture studies.
Recently, an association of chemerin
serum levels with metabolic syndrome–
related parameters including BMI (5–7),
FI (7), triglycerides (6–8), HDL choles-
terol (5–8), leptin (5,6), and CRP (5,6)
has been shown. In agreement with these
ﬁndings,chemerinispositivelycorrelated
with BMI, FI, leptin, and CRP in univari-
ate analyses in the control patients in our
study. However, these associations in
control patients are all lost in multivariate
analyses after controlling for renal func-
tion, whereas GFR remains independently
associated with circulating chemerin. In-
terestingly, GFR also independently pre-
dicts chemerin serum levels in the CD
patients in our study. These results indi-
cate that renal function is a signiﬁcant
predictorofcirculatingchemerinnotonly
insubjectswith(near)normalglomerular
ﬁltration but also in patients with end-
stage renal disease.
Some limitations of the study have to
be pointed out: First, the study has a
cross-sectional design, and, therefore,
causality cannot be established. Second,
thesamplesizeisrelativelysmall,anditis
possible that various nonsigniﬁcant asso-
ciations in multivariate analyses would
have become statistically signiﬁcant if
largersampleswerestudied.Third,differ-
ential misclassiﬁcation of covariates such
astype2diabetesispossiblebecausetype
2 diabetes was only excluded in the con-
trol patients but not in the CD patients by
75-g oral glucose tolerance tests due to
the necessary ﬂuid restriction in the latter
group.
Taken together, our results suggest
that renal ﬁltration independently pre-
dicts circulating chemerin.
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